NewsSeeking Partnerships: Biomed Industries Inc. Developing Groundbreaking Diabetes/Obesity Drug

Seeking Partnerships: Biomed Industries Inc. Developing Groundbreaking Diabetes/Obesity Drug

In a recent announcement, Biomed Industries, Inc. (Biomed) shared the news of their latest development – a cutting-edge obesity drug known as NA-921, which is currently gearing up for Phase 2/3 clinical trials. NA-921 is a unique small molecule drug that can be taken orally.

Biomed is currently in talks with potential partners for a collaboration that would facilitate a Phase 3 trial of NA-921. This drug shows significant promise as a potential treatment for diabetic obesity.

NA-921 is a convenient once-a-day oral capsule that operates based on a novel mechanism involving GLP-1 and IGF-1. The Company has recently applied for patent protection for this formulation. Interestingly, a similar analogue/prodrug of NA-921 has already been granted approval by the FDA for the treatment of a rare disease, leading to separate licensing discussions for Biomed.

Dr. Lloyd Tran, Chairman and CEO of Biomed Industries, expressed enthusiasm about the new drug, stating, “We are actively seeking collaborators to work with us on this exciting new approach for the treatment of Diabetes and Obesity. NA-921 is novel in its approach to targeting both GLP-1 and IGF-1. The drug has shown only minor adverse events in a Phase 2A trial. We believe that this new approach will provide a clear choice for patients wanting to have a much more convenient way to take an obesity drug as well as minimize side-effects they experience with current treatments.”

About Biomed Industries, Inc.
Biomed Industries™, Inc. is a trailblazing bio-pharmaceutical company that is dedicated to innovating, developing, and commercializing revolutionary drug therapeutics that address unmet medical needs. Biomed is at the forefront of cutting-edge discoveries with its new range of clinical drugs that target various conditions like Alzheimer’s disease, MDD, Rett Syndrome, and now Diabetes/Obesity. Furthermore, the company is exploring the integration of AI for drug discovery, improving clinical trial procedures, and other critical areas within the pharmaceutical and medical device industries.

For more information, please visit Biomed Industries, Inc.

Contact Information:

Biomed Industries, Inc.
Michael Willis
Phone: 800-824-5135
Website: www.biomedind.com

ContactContact

Categories

  • Pharmaceuticals

 » …
Read More rnrn

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Subscribe Today

GET EXCLUSIVE FULL ACCESS TO PREMIUM CONTENT

SUPPORT NONPROFIT JOURNALISM

EXPERT ANALYSIS OF AND EMERGING TRENDS IN CHILD WELFARE AND JUVENILE JUSTICE

TOPICAL VIDEO WEBINARS

Get unlimited access to our EXCLUSIVE Content and our archive of subscriber stories.

Exclusive content

Latest article

More article